Share Price | Neurogene, Inc. Stock Analysis & Recommendation

Q: What does Neurogene, Inc. do?

Overview:Neurogene, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.Financial Snapshot:Most recent Net Sales: Not availableMost recent Net Profit: Not availableMarket-cap: Micro CapKey Metrics:Industry: Pharmaceuticals & BiotechnologyMarket cap: Micro CapDividend Yield: 0.00%Debt Equity: -999,999.00Return on Equity: -999,999.00%Price to Book: 0.00Contact Details:Registrar Address: Not available.

Q: Is Neurogene, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Neurogene, Inc. has changed from sideways to mildly bullish. However, the overall technical stance remains mixed. The weekly MACD is bearish while the monthly MACD is mildly bullish. Moving averages indicate a mildly bullish trend on the daily timeframe. The Bollinger Bands and KST show bearish signals on the weekly, with the KST also bearish on the monthly. Dow Theory presents a mildly bearish stance on the weekly but is mildly bullish on the monthly.Despite the mildly bullish trend change, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -18.29% versus the S&P 500's 12.22%, and a one-year return of -54.77% compared to 17.14% for the index. Overall, the indicators suggest a cautiously optimistic outlook, but the bearish signals in the weekly timeframe indicate potential risks.

Results Declared: Neurogene, Inc. has declared results on 24 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

35.35 k

Shareholding (Dec 2025)

FII

10.13%

Held by 43 FIIs

DII

53.87%

Held by 23 DIIs

Promoter

15.11%

What does Neurogene, Inc. do?

22-Jun-2025

Neurogene, Inc. is a Micro Cap company in the Pharmaceuticals & Biotechnology industry. It currently has no available net sales or profit, a 0.00% dividend yield, and significant negative debt equity and return on equity metrics.

View full answer

Is Neurogene, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Neurogene, Inc. shows a mildly bullish trend change, but mixed technical indicators and significant underperformance compared to the S&P 500 suggest a cautiously optimistic outlook with potential risks.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 334 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-999,999.00%

Price to Book

1.26

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-25 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

5.15%

6 Months

20.5%

1 Year

124.34%

2 Years

-53.7%

3 Years

54.71%

4 Years

-41.14%

5 Years

-91.39%

Neurogene, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-190.82%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

88.83%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.26

EV to EBIT

-0.74

EV to EBITDA

-0.76

EV to Capital Employed

22.20

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-3008.97%

ROE (Latest)

-32.06%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 26 Schemes (20.89%)

Foreign Institutions

Held by 43 Foreign Institutions (10.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -26.67% vs -25.81% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.70",
          "val2": "-20.70",
          "chgp": "-28.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.70",
          "val2": "-19.50",
          "chgp": "-26.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -20.37% vs -106.89% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-100.00",
          "val2": "-79.40",
          "chgp": "-25.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-90.40",
          "val2": "-75.10",
          "chgp": "-20.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-89,302.70%",
          "chgp": "8,930.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-26.70

-20.70

-28.99%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-24.70

-19.50

-26.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -26.67% vs -25.81% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

0.90

-100.00%

Operating Profit (PBDIT) excl Other Income

-100.00

-79.40

-25.94%

Interest

0.00

Exceptional Items

-0.10

0.00

Consolidate Net Profit

-90.40

-75.10

-20.37%

Operating Profit Margin (Excl OI)

0.00%

-89,302.70%

8,930.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -20.37% vs -106.89% in Dec 2024

All Annual Results

Company CV

About Neurogene, Inc.

Neurogene, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available